噻唑烷二酮类药物对原发性高血压患者颈动脉内膜中层厚度及氧化低密度脂蛋白的作用

Role of Thiazolidinediones on the intima-media thickness and ox-LDL in patients with primary hypertension

目的分析噻唑烷二酮类药物对原发性高血压(PH)患者颈动脉内膜中层厚度(IMT)及氧化低密度脂蛋白(ox-LDL)的作用。方法选择本院2010年2月~2014年2月符合标准的100例PH患者进行研究。依据治疗措施将患者分为两组:治疗组(n=50)与对照组(n=50)。所有患者均采用常规降压、调脂治疗,治疗组另加上罗格列酮4~8 mg/d,控制血压在140/90 mm Hg以下。在0、3、6、12个月测定患者的IMT及ox-LDL水平。结果治疗3、6、12个月后,患者的IMT明显降低,ox-LDL水平明显下降(P<0.05),且治疗组患者变化比对照组更显著,且差异有统计学意义(P<0.05)。结论噻唑烷二酮类药物可明显降低PH患者的IMT及ox-LDL水平。

Objective To analyze the role Thiazolidinediones on the intima-media thickness and ox-LDL in patients with primary hypertension（PH）.Methods 100 patients with PH meeting the standard in our hospital from February2010 to February 2014 were selected.Patients were divided into two groups：control group（n=50） and treatment group（n =50）.All patients were treated with routine antihypertensive and lipid modulating,and treatment group was plused Rosiglitazone 4-8 mg/d,control of blood pressure was in below 140/90 mm Hg.The IMT and ox-LDL level of patients were measured in 0,3,6 and 12 months.Results After 3,6 and 12 months treatment,IMT was decreased greatly and oxLDL level was decreased greatly（P〈0.05）.Change of treatment group was obvious compared with control group,and there was a statistical difference（P〈0.05）.Conclusion Thiazolidinediones can obviously decrease IMT and ox-LDL level of patients.